Immunosuppression Derived from Human B-Lymphoblastoid and Melanoma Cell Lines

References

• Fontana A, Hengartner H, DeTribolet N, Weber E. Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects. J Immunol 1984; 132(4)1837–1844
   PubMed Web of Science ®Google Scholar
• Klein H G, Leitman S F. Adoptive immunotherapy in the treatment of malignant disease. Transfusion 1989; 29(2)170–178
   PubMed Web of Science ®Google Scholar
• Radrizzani M, Gambacorti-Passerni C, Parmiani C, Fossati G. Lysis by interleukin 2-stimulated tumor-infiltrating lymphocytes of autologous and allogenic tumor target cells. Cancer Immunol Immunother 1989; 28: 67–73
   PubMed Web of Science ®Google Scholar
• Rosenberg S A, Schwarz S L, Spiess P J. Combination immunotherapy for cancer: Synergistic antitumor interactions of interleukin-2, alfe-interferon, and tumor-infiltrating lymphocytes. J Natl Cancer Inst 1988; 80(17)1393–1397
   PubMed Web of Science ®Google Scholar
• Itoh K, Tilden A B, Balch C M. Role of interleukin 2 and a serum suppressive factor on the induction of activated killer cells cytotoxic for autologous human melanoma cells. Cancer Res 1985; 45: 3173–3178
   PubMed Web of Science ®Google Scholar
• Guillou P J, Sedman P C, Ramsden C W. Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro. Cancer Immunol Immunother 1989; 28: 43–53
   PubMed Web of Science ®Google Scholar
• Kuppner M C, Hamou M, Bodmer S. The glioblastoma-derived T-cell suppressor factor/transforming growth factor beta2 inhibits the generation of lymphokine-activated killer (LAK) cells. Int J Cancer 1988; 42: 562–567
   PubMed Web of Science ®Google Scholar
• Pledger W J. Regulation of cell proliferation: Serum growth factors control an ordered series of Gl events. Control of Cell Growth and Proliferation, CM Venziale. Van Nostrand Reinhold, New York 1985; 10–126
   Google Scholar
• Goustin A S, Leof E B, Shipley G D, Moses H L. Growth factors and cancer. Cancer Res 1986; 46: 1015–1029
   PubMed Web of Science ®Google Scholar
• Morrone G, Corbo L, Turco M C. Transferrin-like autocrine growth factor, derived from T-lymphoma cells, that inhibits normal T-cell proliferation. Cancer Res 1988; 48: 3425–3429
   PubMed Web of Science ®Google Scholar
• Ensoli B, Nakamura S, Salahuddin S Z. AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science 1989; 243: 223–243
   PubMed Web of Science ®Google Scholar
• Oh S, Moolton F L. Nonspecific immunosuppressive factors in malignant ascites: further characterization and possible relationship to erythrocyte receptors of human peripheral T cells. J Immunol 1981; 127: 2300–2307
   PubMed Web of Science ®Google Scholar
• Remacle-Bonnet M M, Pommier G J, Kaplanski S. Inhibition of normal allogenic lymphocyte mitogenesis by a soluble inhibitor extracted from human colonic carcinoma. J Immunol 1976; 117: 1145–1151
   PubMed Web of Science ®Google Scholar
• Roth J A, Osborne B A, Ames R S. Immunoregulatory factors derived from human tumors. J Immunol 1983; 130: 303–308
   PubMedGoogle Scholar
• Levy J A, Buell D N, Creech C. Characterization of WIL-1 and WIL-2 cell lines. J Natl Cancer Inst 1971; 46(3)647–652
   PubMed Web of Science ®Google Scholar
• Levy J A, Virolainen M, Defendi V. Human lymphoblastoid lines from lymph node and spleen. Cancer 1988; 22(3)517–524
   Google Scholar
• Glassy M C, Handley H H, Hagiwara H, Royston I. UC729–6, a human lymphoblastoid B-cell line useful for generating antibody secreting human hybridomas. Proc Natl Acad Sci (USA) 1983; 80: 6327–6331
   PubMed Web of Science ®Google Scholar
• Schulz G, Bumol T F, Resifeld R A. Monoclonal antibody-directed effector cells selectively lyse human melanoma cells in vitro and in vivo. Proc Natl Acad Sci (USA) 1983; 80: 5407–5411
   PubMed Web of Science ®Google Scholar
• Gebhard K J, Gridley D S, Stickney D R, Shultz T D. Enhancement of immune status by high levels of dietary vitamin B-6 without growth inhibition of human malignant melanoma in nude mice. Nutr Cancer 1990; 14: 15–26
   PubMed Web of Science ®Google Scholar
• Shultz T D, Santamaria A G, Gridley D S. Effect of pyridox-ine and pyridoxal on the in vitro growth of human malignant cells. Anticancer Res 1988; 8: 1313–1318
   PubMed Web of Science ®Google Scholar
• Takahashi K, Ono K, Hirabayashi Y, Taniguchi M. Escape mechanisms of melanoma from immune system by soluble melanoma antigen 1988; 140: 3244–3248
   Google Scholar
• Nelson M, Nelson D S. Inhibition of cell mediated immunity by tumour cell products: Depression of interleukin-2 production and responses to interleukin-2 by mouse spleen cells. Immunol Cell Biol 1988; 66: 97–104
   PubMed Web of Science ®Google Scholar
• Macdonald H R, Habholz M. T-cell activation. Ann Rev Cell Biol 1986; 2: 23–53
   Google Scholar
• Shirakawa F, Tanaka Y, Oda S. Immunosuppressive factors from adult T-cell leukemia cells. Cancer Res 1986; 46: 4458–4462
   PubMed Web of Science ®Google Scholar
• Putnam J B, Roth J A. Identification and characterization of a tumor-derived immunosuppressive glycoprotein from murine melanoma K-1735. Cancer Immunol Immunother 1985; 19: 90–100
   PubMed Web of Science ®Google Scholar
• Ebert E C, Al Roberts, O'Connell S M, Robertson F M, Nagase H. . Characterization of an immunosuppressive factor derived from colon cancer cells. J Immunol 1987; 138: 2161–2168
   PubMed Web of Science ®Google Scholar
• Cornelius J G, Normann S J. Isolation of a low molecular weight inhibitor of lymphocyte proliferation from tumorous ascites. J Immunol 1988; 141: 2175–2180, Repique, Kettering, and Gridley
   PubMed Web of Science ®Google Scholar
• Koga T, Nakano S, Ichinose I. Characterization of a low-molecular-weight growth inhibitor formed by density inhibited, tumorigenic V79 Chinese hamster cells. Cancer Res 1988; 48: 3737–3741
   PubMed Web of Science ®Google Scholar
• Wolf R I, Ilekis J, Benveniste R. Characterization of an immune suppressor from transformed human trophoblastic JEG-3 cells. Cell Immunol 1983; 78: 356–367
   PubMed Web of Science ®Google Scholar
• Blumenthal R, McLaughlin W, Jordan J, Cryan E, Bloomer W. Secretion of a growth inhibitory factor by ZR-75–1 human breast cancer cells. Biochem Biophys Res Comm 1987; 149(2)642–646
   PubMed Web of Science ®Google Scholar
• Funkhouser W K, Neckers L M, Ames R S. Inhibition of DNA synthesis by a small-cell lung carcinoma-derived protein. J Natl Cancer Inst 1986; 77(4)925–932
   PubMed Web of Science ®Google Scholar
• Cheung N V, Lazarus H, Miraldi F D. Ganglioside-GD2-specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 1987; 5: 1430–1440
   PubMed Web of Science ®Google Scholar
• Mertin J, Hughes D. Specific inhibitory action of polyunsaturated fatty acids on lymphocyte transformation induced by PHA and PPD. Int Arch Allergy Applied Immunol 1975; 48: 203–210
   PubMedGoogle Scholar
• Young M R, Sundharadas G, Cantarow W D, Kuimar P R. Purification and functional characterization of a low molecular weight immune modulating factor produced by Lewis lung carcinoma. Int J Cancer 1982; 30: 517–524
   PubMed Web of Science ®Google Scholar
• Meade C J, Mertin J. Fatty acids and immunity. Adv Lipid Res 1978; 16: 127–130
   PubMedGoogle Scholar
• Owen K, Gomolka D, Droller M J. Production of prostaglandin E-2 by tumor cells in vitro. Cancer Res 1980; 40: 3167–3171
   PubMed Web of Science ®Google Scholar
• Bernhard H, Meyer zum Buschenfelde K H, Dippold W G. Ganglioside GD3 shedding by human malignant melanoma cells. Int J Cancer 1989; 44: 155–160
   PubMed Web of Science ®Google Scholar
• Pukel C S, Lloyd K O, Travassos L R. GD3 a prominent ganglioside of human melanoma. J Exp Med 1982; 115: 1133–1147
   Google Scholar
• Merritt W D, Bailey J M, Pluznik D H. Inhibition of interleukin-2-dependent cytotoxic T-lymphocyte growth by gangliosides. Cell Immunol 1984; 89: 1–10
   PubMed Web of Science ®Google Scholar
• Ladisch S, Gillard B, Wong C, Ulsh L. Shedding and immunoregulatory activity of YAC-1 lymphoma cell gangliosides. Cancer Res 1983; 43: 3308–3318
   Google Scholar
• Gonwa T A, Westrick M A, Macher B A. Inhibition of mitogen-and antigen-induced lymphocyte activation by human leukemia cell gangliosides. Cancer Res 1984; 44: 3467–3470
   PubMed Web of Science ®Google Scholar
• Prabhu Das M, Gridley D S, Kettering J D. Suppression of immune response by herpes virus type 2-transformed murine tumor cells. Immunol Letters 1991; 30: 37–46
   PubMed Web of Science ®Google Scholar